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Abstract A rat cortical spreading depression (CSD)
model was established to explore whether cerebral mito-
chondria injury was induced by CSD under both normoxic
and hypoxic conditions and whether ﬂunarizine had a
protective effect on cerebral mitochondria. SD rats, which
were divided into seven groups, received treatment as
follows: no intervention (control Group I); 1 M NaCl
injections (Group II); 1 M KCl injections (Group III);
intraperitoneal ﬂunarizine (3 mg/kg) 30 min before KCl
injections (Group IV); 14% O2 inhalation before
NaCl injections (Group V); 14% O2 inhalation followed by
KCl injections (Group VI); 14% O2 inhalation and intra-
peritonealﬂunarizinefollowedbyKClinjections(GroupVII).
Following treatment, brains were removed for the analysis
of mitochondria transmembrane potential (MMP) and
oxidative respiratory function after recording the number,
amplitude and duration of CSD. The duration of CSD was
signiﬁcantly longer in Group VI than that in Group III. The
number and duration of CSD in Group VII was signiﬁ-
cantly lower than that in Group VI. MMP in Group VI was
signiﬁcantly lower than that in Group III, and MMP in
Group VII was signiﬁcantly higher than that in Group VI.
State 4 respiration in Group VI was signiﬁcantly higher
than that in Group III, and state 3 respiration in Group VII
was signiﬁcantly higher than that in Group VI. Respiration
control of rate in Group VII was also signiﬁcantly higher
than that in Group VI. Thus, we concluded that aggravated
cerebral mitochondria injury might be attributed to CSD
under hypoxic conditions. Flunarizine can alleviate such
cerebral mitochondria injury under both normoxic and
hypoxic conditions.
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Introduction
Cortical spreading depression (CSD) is a self-propagating
wave of cellular depolarization that has been implicated in
migraine and in progressive neuronal injury after stroke
and head trauma.CSD which was ﬁrst described by Leao
[1], comprises a wave of reversible EEG suppression that
propagates at a rate of 2–3 mm/min across the cortical
surface, accompanied by a negative deﬂection of the direct
current (DC) potential and a severe disruption in ion
homeostasis [2, 3]. Recovery from CSD depends upon ion
pump activity to cause an increase in metabolic activity
and oxygen demand [4–6]. In normal brain tissue, this
chain of events is partially compensated by an increase in
cerebral blood supply [6, 7]. This coupling will be dis-
turbed in tissues which lack oxygen. Mitochondria are key
to both apoptotic and necrotic brain cell death. Several
prominent mitochondrial alterations, including changes in
mitochondrial respiratory function and mitochondrial
membrane potential (MMP) [8], accompanied by hypoxia
can contribute to cell death. A variety of electrophysio-
logical, visual and psychological events have indicated that
CSD-like events occur during the initiation of migraines
[9–13], and usually, but not always, a cerebral oligemia is
the only cerebral vascular response consistently detected in
these circumstances [14–16]. Cellular hypoxia, in turn, can
cause an increase in the ﬂow of calcium from the extra-
cellular ﬂuid to the intracellular space, resulting in calcium
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DOI 10.1007/s10194-011-0300-1overload and cellular dysfunction. The piperazine deriva-
tive ﬂunarizine, a non-selective calcium antagonist [17],
shown in many controlled clinical studies to be effective in
migraine prophylaxis [18–26], has been found to protect
brain tissue against hypoxic damage [27]. Therefore, the
purpose of this study is to explore whether cerebral mito-
chondrial injury is related to CSD under both normoxic and
hypoxic conditions and to ﬁnd whether ﬂunarizine has a
protective effect on cerebral mitochondria.
Methods
This study on animals complies with the prevailing stan-
dards of animal welfare embodied in UK laws governing
animal experimentation.
Rats’ surgical preparation
CSD male rats (220–250 g) were placed in individual
cages in a thermoregulated (22C), 12 h night/12 h day
room. They were allowed free access to water but fasted
for 12–16 h before surgery. Rats (n = 58) were anesthe-
tized with urethane via a 20% oxygen-balance nitrogen
mixture. Then they were warmed by a heating lamp
(37 ± 0.5C) above their dorsal surface during surgical
procedures and controlled via a rectal temperature probe. A
tail artery was cannulated for sampling blood and moni-
toring arterial blood pressure.
A 2–3 mm left parasagittal skin incision was made from
the midline. The wound edges were spread and the skull
bone scraped. Then two small (1–2 mm diameter) craniot-
omies were drilled. The former was 2 mm lateral and 3 mm
anterior to bregma, while the latter was 6 mm posterior and
5 mm lateral to bregma [28]. Both craniotomies were
carefully drilled so that the underlying dura would not be
torn. CSD was induced by microinjection of KCl via a
microinjector placed 1 mm below the pial surface of the
posterior craniotomy. 0.5 ll KCl (1 M) was injected every
10 min within 1 h. Rats of Group II or Group V were
injected with NaCl (1 M) at an analogous dose and fre-
quency.Aglassmicropipette(tipdiameter,1 lm;ﬁlledwith
0.5 M sodium acetate) was positioned 1 mm below the pial
surface through the anterior craniotomy to monitor DC
neocorticalpotentialsandtoconﬁrmwhetherCSDoccurred.
Microelectrodes were connected to an ampliﬁer system, and
then DC signals were displayed on a chart recorder. An
indifferent electrode was positioned in the left neck muscle.
Animal groups
Fifty-six SD rats were divided into seven groups randomly
with each group consisting of eight rats. Group I was the
control group. Group II received 1 M NaCl injections to
the left parietal cortex. Group III received 1 M KCl
injections to the left parietal cortex. Group IV received an
intraperitoneal dose of ﬂunarizine (3 mg/kg) 30 min before
KCl injections mentioned above in Group III. Group V
inhaled 14% O2 for 30 min before 1 M NaCl injections.
Group VI inhaled 14% O2 for 30 min before 1 M KCl
injections. Group VII inhaled 14% O2 for 30 min and
received an intraperitoneal dose of ﬂunarizine (3 mg/kg)
30 min before the 1 M KCl injections.
Mitochondrial oxidative respiratory function and MMP
Fresh mitochondria were isolated from cerebral cortex as
described by Clark [29]. The brain was placed in an ice-cold
isolation media containing 0.25 M sucrose, 0.5 mM EDTA
(dipotassium salt) and Tris–HCl (pH 7.4) immediately after
the removal. The cerebral cortex was ﬁnely minced with
scissors and homogenized with isolation buffer in an all-
glass Teﬂon homogenizer. The homogenate was centri-
fuged at 2,0009g for 3 min, and the supernatant was
carefully decanted and saved. The pellet was resuspended in
half of the original volume of isolation buffer and centri-
fuged in the way mentioned above. The supernatant was
saved and the pellet was discarded. The pooled supernatants
were centrifuged at 12,5009g for 8 min. The resulting
pellet was resuspended in 3% Ficoll solution, layered in 6%
Ficoll solution, and then centrifuged at 11,5009g for
30 min. The pellet was resuspended in an appropriate vol-
ume of isolation buffer, and centrifuged at 12,0009g for
8 min. All the procedures were completed at 0–4C within
90 min. The concentration of mitochondrial protein was
measured by the Lowry method. The puriﬁed mitochondrial
fraction was used for mitochondrial respiration and mito-
chondrial membrane potential measurements.
Oxygen uptake of isolated mitochondria (nmol O2/min
per mg protein) was determined by polarography using a
Clark-type oxygen electrode at 28C as described by
Cha ´vez [30]. The pellet of mitochondria obtained from
ﬁnal centrifugation was resuspended and transferred to the
oxygen electrode chamber in 800 ll buffer which con-
tained 100 mM KCl, 75 mM mannitol, 25 mM sucrose,
5 mM potassium phosphate, 0.05 EDTA (K
? salt) and
10 mM Tris–HCl (pH 7.4). 5 mM pyruvate plus 2.5 mM
malate were included as substrates. Incubation conditions
for determining state 3 (ST3) (ADP and substrates present)
and state 4 respiration (ST4) (after ADP was depleted)
were as deﬁned by Chance and Williams [31]. Respiration
control rate (RCR) is deﬁned as ST3 divided by ST4.
Hundred microliter of mitochondria obtained from ﬁnal
centrifugation, 2.5 lM rotenone and 1 lM rhodamine 123
were resuspended and transferred to 1 ml of reaction
media which contained 150 mM sucrose, 5 mM sodium
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123succinate, 5 mM K3PO4, 20 mM HEPES and 5 mM
MgCl2. 5 min later, the mixed solution was centrifuged at
5,0009g for 5 min at room temperature.
[Rhodamine 123]out was made with a spectrophotometer
at 500 nm. Membrane potentials (negative inside) were
calculated by the Nernst equation: Mitochondria membrane
potentials (MMP) = 59 log ([X]in/[X]out). [Rhodamine
123]in was estimated from rhodamine 123 uptake assuming
distribution into a matrix space of 1 ll/mg of protein [32].
Statistical analysis
The data of duration of CSD in each group are expressed as
median 25% quartile to 75% quartile, and statistical anal-
ysis is performed using K related samples test. The other
data are expressed as means ± SEM, and statistical anal-
ysis is performed using ANOVA, followed by post hoc
Fisher’s test. Software SPSS 13.0 is used. Signiﬁcance is
assumed at P\0.05.
Results
Cortical spreading depression
About 3 min after KCl injection, CSD was induced in rats
of Group III, Group IV, Group VI and Group VII (see
Fig. 1). The manifestation of CSD in Group III was an
extracellular negative potential with amplitude of
10–30 mV and duration of 0.5–1.5 min, which may be
preceded or succeeded by a positive deﬂection of variable
amplitude and duration. The manifestation of CSD in
Group IV, Group VI, and Group VII was similar to that in
Group III. There was no CSD recorded in Group II and
Group V.
The duration of CSD in Group V was signiﬁcantly
longer than that in Group III (P\0.01). The number of
CSD in Group IV was signiﬁcantly less than that in Group
III (P\0.01). The amplitude of CSD in Group IV was
signiﬁcantly smaller than that in Group III (P\0.05). The
duration of CSD in Group IV was signiﬁcantly shorter than
that in Group III (P\0.01). The number of CSD in Group
VII was signiﬁcantly less than that in Group VI (P\0.05)
(Table 1). The duration of CSD in Group VII was signiﬁ-
cantly shorter than that in Group VI (P\0.01) (Table 2).
Mitochondrial oxidative respiratory function
ST3 in Group VI was signiﬁcantly lower than that in Group
I and Group II (P\0.01). ST3 in Group VII was signiﬁ-
cantly higher than that in Group VI (P\0.05). ST4 in
Group VI was signiﬁcantly higher than that in Group I and
Group II (P\0.01). RCR of Group VI was signiﬁcantly
Group IV
Group VI Group VII
Group II Group V
Group III
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1
0
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Fig. 1 The manifestation of CSD
Table 1 The number and amplitude of CSD (mean ± SD)
Group Number Amplitude (mv)
Group III 9.25 ± 3.81 14.54 ± 6.05
Group IV 3.88 ± 4.05** 11.75 ± 4.13*
Group VI 8.63 ± 2.67 16.91 ± 6.12
Group VII 5.00 ± 3.16*
,D 15.29 ± 3.39
* P\0.05 versus Group III; ** P\0.01 versus Group III;
D P\0.05 versus Group VI
Table 2 The duration of CSD in each group
Group Duration (s)
Group III 59 (49.5–72.5)
Group IV 55 (50–62)*
Group VI 75 (64–92)**
Group VII 65 (58.5–79)**
,DD
The values are median (25% quartile–75% quartile)
* P\0.05 versus Group III; ** P\0.01 versus Group III;
DD
P\0.01 versus Group VI
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123lower than that in Group I (P\0.01). RCR of Group VII
was signiﬁcantly higher than that in Group VI (P\0.01)
(Table 3).
MMP
MMP in Group III (P\0.01) and Group VI (P\0.05)
was signiﬁcantly lower than that in Group I. MMP in
Group VI was signiﬁcantly lower than that in Group
III(P\0.01). MMP in Group IV was signiﬁcantly higher
than that in Group III (P\0.01). MMP in Group VII was
signiﬁcantly higher than that in Group VI (P\0.01)
(Table 4).
Discussion
CSD is now recognized to be probably the neurophysio-
logical substrate of classical migraine aura, and may be
involved in migraines without a perceived aura as well,
although it has also been a focus of intense investigation in
relation to apparently diverse disease states including
ischemic or hemorrhagic stroke and head trauma [33].
Several recent descriptions of CSD in humans in the setting
of brain injury provide deﬁnitive evidence that this phe-
nomenon can occur and have important functional
consequence in the human brain. Mayevsky and colleagues
[34] used an invasive multiparametric monitoring system
to record reduction of electroencephalogram (EEG)
amplitude, and an increase in extracellular K
? in a patient
with severe head injury. Strong and colleagues [35] used
electrodes placed near foci of damaged cortical tissue in
patients with intracranial or subarachnoid hemorrhage to
record propagated depression of electrocorticographic
(ECoG) activity whose rate of spread was the same as that
of CSD. Despite the longstanding assumption that CSD is
the primary mechanism underlying the migraine aura, there
has yet been no deﬁnitive demonstration of the electro-
physiological features of CSD in a migraine patient. The
spatial and temporal characteristics of migraine aura
symptoms and of the propagated changes in blood ﬂow and
functional MRI signal observed in migraine patients are
certainly consistent with CSD [36]. However, surface EEG
recording in migraine patients, including a few documented
patients with migraine with aura, have not demonstrated
the classical electrophysiological features of CSD [37]. This
may be because surface EEG does not have the sensitivityto
detect CSD. Recent studies suggest that spreading depres-
sioncouldbetheﬁnalcommonpathophysiologicaltargetfor
several established or investigational migraine prophylactic
drugs [33]. Five clinically effective migraine prophylactic
drugs (valproate, topiramate, propranolol, amitriptyline,
methysergide) were shown to suppress SD susceptibility
[38]. Flunarizine showed a somewhat dose-dependent CSD
suppression [39].
The number of CSD represents the susceptibility of the
cortex to CSD. In this study, the number of CSD under
both normoxic and hypoxic conditions was examined.
Decreasing the percentage of O2 from room air concen-
tration (21%) to 14% did not change the number of CSD.
Takano [6] observed that decreasing the percentage of
O2 from room air concentration (21%) to 8% generated
CSD without KCl injection. From the two experiments,
we concluded that the susceptibility of cortex to CSD
increased at 8–14% O2. The susceptibility of the cortex to
CSD is also affected by many other factors including
Table 3 Mitochondrial oxidative respiratory function (mean ± SD)
Group ST3 (nmol/min/mg pro) ST4 (nmol/min/mg pro) RCR
Group I 103.05 ± 21.73 18.29 ± 7.15 6.18 ± 2.02
Group II 102.27 ± 8.88 18.36 ± 5.66 6.04 ± 2.05
Group III 82.47 ± 24.00 29.26 ± 12.12 3.14 ± 1.46
Group IV 89.39 ± 33.95 29.16 ± 17.61 4.54 ± 1.06
Group V 93.35 ± 22.02 43.05 ± 16.68**
,DD 3.30 ± 1.44
Group VI 61.73 ± 23.44**
,mm 45.66 ± 18.11**
,e 1.36 ± 0.35**
Group VII 86.28 ± 19.28
q 37.62 ± 11.19** 2.34 ± 0.36*
,qq
* P\0.05 versus Group I; ** P\0.01 versus Group I;
DD P\0.01 versus Group II;
e P\0.05 versus Group III;
mm P\0.01 versus Group
V;
q P\0.05 versus Group VI;
qq P\0.01 versus Group VI
Table 4 MMP in each group (mean ± SD)
Group MMP (mv)
Group I 194.30 ± 10.58
Group II 188.94 ± 7.25
Group III 161.89 ± 14.99**
,DD
Group IV 179.06 ± 11.60*
,ee
Group V 182.59 ± 8.21
Group VI 144.78 ± 19.20**
,ee,mm
Group VII 174.27 ± 8.94**
,qq
* P\0.05 versus Group I; ** P\0.01 versus Group I;
DD P\0.01
versus Group II;
ee P\0.01 versus Group III;
mm P\0.01 versus
Group V;
qq P\0.01 versus Group VI
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123cytoarchitecture, maturity and distribution of transmitter
systems, ion channels in the neuron membrane and pH [40].
The wave of CSD is produced by neuron dendritic
persistent inward currents. The amplitude of CSD is reg-
ulated by glutamate-controlled channels, sodium channels
and calcium channels [41, 42]. In the present study, the
amplitude of CSD under normoxic and hypoxic conditions
was examined. Decreasing the percentage of O2 from room
air concentration (21%) to 14% did not change the
amplitude of CSD. Therefore, we concluded that the
amplitude of CSD was not affected by O2 concentration.
The duration of CSD is related to the repolarization of
neurons and glial cells. During this study, we found an
inverse correlation between O2 supply and the duration of
CSD. The ﬁnding implied that O2 supply was the important
factor for normalization of extracellular K
?.
Flunarizine is reported to be the only calcium antagonist
capable of protecting brain cells against hypoxic damage
[42, 43]. Results of more than 10 open and almost 20 pla-
cebo-controlled trials of migraine prophylaxis with ﬂu-
narizine demonstrate the beneﬁcial effects and safety of this
agent [18]. Meanwhile, eight clinical trials compared the
calcium channel blocker with b-adrenoceptor blockers (six
trials with propranolol, two with metoprolol) [19–26], in
which ﬂunarizine was equally effective with the b-adreno-
ceptor blockers, but had a qualitatively different adverse
event proﬁle. Hence, ﬂunarizine is considered a drug of ﬁrst
choice in migraine prophylaxis, and is used as ﬁrst-line
prophylactic agents in most European countries [44].
In the present study, it was found that ﬂunarizine
decreased the number and amplitude of CSD, and short-
ened the duration of CSD under normoxic conditions. Also
it was found that ﬂunarizine decreased the number and
duration of CSD under hypoxic conditions.
Flunarizine reduced the susceptibility of the cortex to
CSD under normoxic and hypoxic conditions. Blockers of
L-, N-, and P/Q-type voltage-gated calcium channels
decreased the number of CSD [45]. These results suggested
the effects of ﬂunarizine on the number of CSD can be
attributed to its blockers of L-, N-type voltage-gated cal-
cium channels.
Flunarizine shortened the duration of CSD under both
normoxic and hypoxic conditions, which may be attributed
to its inhibitory effect on cortical hypoperfusion induced by
CSD [46]. Thus, O2 supply in brain tissue is increased,
which allowed the repolarization of neurons and glial cells.
Flunarizine decreased the amplitude of CSD under
normoxic conditions, which may be attributed to the
amplitude of CSD regulated by calcium antagonist [40].
Flunarizine did not decrease the amplitude of CSD under
hypoxic conditions. This ﬁnding indicated that hypoxia
attenuated the effect of calcium antagonists on the ampli-
tude of CSD.
Whether CSD can cause irreversible neuronal injury or
not is uncertain. As mentioned by Nedergaard and Hansen
[47], in normally circulated and oxygenated healthy adult
brains, SD can be provoked many times without obvious
harm. Pomper et al. [48] report that repeated episodes of
spreading depression-like events (SDLEs) caused irre-
versible injury in hippocampal slice cultures taken from
immature brains. Mitochondria have many functions in
eukaryotic cells. Perhaps the most important one is the
generation of adenosine 50-triphosphate (ATP) by oxidative
phosphorylation. Since it had been shown that tissue ATP
content decreases to 54% in rats during the passages of SD
waves, the capability of tissue energy production has been
studied [49]. The mitochondrial redox state inclines to the
reduction side synchronous to the onset of CSD and nor-
malizes within 120 s after the onset of depolarization by
measuring the NADH ﬂuorescence in vivo [50]. Along
with many mitochondrial carrier-mediated processes, the
generation of ATP requires an electrochemical potential
generated by the electron transport chain. Thus, normally
functioning mitochondria establish MMP and a pH gradient
(DpH), which jointly comprises Dp, the proton motive
force that drives ATP synthesis. Processes that dissipate
Dp are usually considered harmful to cells. MMP is typi-
cally the more dynamic parameter in the proton motive
force. MMP represents a common ﬁnal pathway of many
conditions associated with oxidative stress including
hypoxia, hypoglycemia, and aging. MMP dissipation may
be caused by ATP synthesis, Ca
2? transport, or the activity
of other carrier proteins [51]. In this study, MMP dissipated
due to CSD and further dissipated due to CSD under
hypoxic conditions. Thus, our data indicated that CSD
caused oxidative stress or aggravated hypoxic conditions in
the brain. These changes can be attenuated by ﬂunarizine.
ST3 reﬂects the maximum rate of coupled respiration,
that is, when electron transport is coupled to ATP synthe-
sis. ST4 reﬂects the rate of leakage of protons back across
the inner mitochondrial membrane into the matrix. RCR
reﬂects the coupling rate of oxidation phosphorylation.
Our data indicated that CSD under hypoxic conditions
decreased the maximal rate of coupled respiration, while
increased the rate of leakage of protons back across the
inner mitochondrial membrane into the matrix, and further
uncoupled the mitochondria. The change of mitochondrial
oxidative respiratory function by CSD under hypoxic
conditions can partly be attenuated by ﬂunarizine.
Theexactpathogenesisofmigraineisnotdeterminedand
may be polymorphic. Platelet mitochondrial enzyme activ-
ities study has shown that NADH-dehydrogenase, citrate
synthase and cytochrome c oxidase activities are signiﬁ-
cantlylowerinmigraineursthanincontrols[52].Adeﬁcient
energy metabolism could be the missing link between the
biobehavioral model and the hypoxia theory of migraine. It
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123would explain why an excessive activation of cortical
structures could lead to trigeminovascular activation via a
metabolic disequilibrium, and possibly via hypoxia-sensing
neurons and the hypoxia-inducible factor [53].
In conclusion, our work indicated that aggravated
cerebral mitochondria injury might be induced by CSD
under hypoxic conditions, and that ﬂunarizine can alleviate
cerebral mitochondria injury under both normoxic and
hypoxic conditions. However, our work is limited to
experimental animals and any link to migraine patho-
physiology is purely hypothetical.
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